Literature DB >> 25059401

The long-term effect of intravitreal ranibizumab on retinal nerve fiber layer thickness in exudative age-related macular degeneration.

Melih Parlak1, F Hakan Oner, A Osman Saatci.   

Abstract

The aim of this study was to evaluate the long-term effect of intravitreal ranibizumab on the retinal nerve fiber layer (RNFL) in exudative age-related macular degeneration (AMD). Patients with treatment naive neovascular AMD in one eye were enrolled into the study. Following 3 monthly intravitreal ranibizumab injections, the patients were evaluated according to disease activity and re-injections were performed according to "treat and extend" protocol. During the follow-up, peripapillary nerve fiber layer thickness measurements were compared with normal fellow eyes. Forty-four eyes of 11 women and 11 men with the mean age of 66.3 ± 8.8 years (50-80) were enrolled into the study. All patients had completed at least 12 months of follow-up time. Patients received an average of 4.7 (3-11 injections) intravitreal injections. At baseline, no significant difference was observed between two groups for RNFL thickness, which was assessed as quadrants (p = 0.250-0.944) and globally (p = 0.814). In each group, there was a significant RNFL thinning (p = 0.009 and 0.022) after the third month, whereas no significant difference was observed between treated and untreated eyes. Patients were also classified according to the number of injections, and RNFL thickness showed no difference between eyes treated with less or more than five intravitreal injections (p = 0.757-0.973). Although there was no statistically significant difference in RNFL thickness between study and control eyes during 12 months of follow-up, a significant thinning was recorded in both groups compared with baseline values. Cross-sectional images with higher resolutions and precise segmentation opportunities are needed to investigate the hypothesis "VEGF neutralization and inhibition of cell maintenance" in detail.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25059401     DOI: 10.1007/s10792-014-9972-2

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN: 0165-5701            Impact factor:   2.031


  22 in total

1.  Lack of therapeutic effect of ranibizumab in fellow eyes after intravitreal administration.

Authors:  Maria-Andreea Gamulescu; Horst Helbig
Journal:  J Ocul Pharmacol Ther       Date:  2010-04       Impact factor: 2.671

2.  Immediate intraocular pressure changes following intravitreal injections of triamcinolone, pegaptanib, and bevacizumab.

Authors:  S J Bakri; J S Pulido; C A McCannel; D O Hodge; N Diehl; J Hillemeier
Journal:  Eye (Lond)       Date:  2007-08-10       Impact factor: 3.775

Review 3.  Age-related macular degeneration.

Authors:  Laurence S Lim; Paul Mitchell; Johanna M Seddon; Frank G Holz; Tien Y Wong
Journal:  Lancet       Date:  2012-05-05       Impact factor: 79.321

4.  Human vascular endothelial growth factor protects axotomized retinal ganglion cells in vivo by activating ERK-1/2 and Akt pathways.

Authors:  Ulkan Kilic; Ertugrul Kilic; Anne Järve; Zeyun Guo; Annett Spudich; Katja Bieber; Uxue Barzena; Claudio L Bassetti; Hugo H Marti; Dirk M Hermann
Journal:  J Neurosci       Date:  2006-11-29       Impact factor: 6.167

5.  Short-term effect of intravitreal injection of Ranibizumab (Lucentis) on intraocular pressure.

Authors:  Maurizio Gismondi; Carlo Salati; Maria L Salvetat; Marco Zeppieri; Paolo Brusini
Journal:  J Glaucoma       Date:  2009-12       Impact factor: 2.503

6.  Retinal nerve fiber layer thickness in normals measured by spectral domain OCT.

Authors:  Delia Bendschneider; Ralf P Tornow; Folkert K Horn; Robert Laemmer; Christopher W Roessler; Anselm G Juenemann; Friedrich E Kruse; Christian Y Mardin
Journal:  J Glaucoma       Date:  2010-09       Impact factor: 2.503

7.  Bevacizumab neutralizes the protective effect of vascular endothelial growth factor on retinal ganglion cells.

Authors:  Vikram S Brar; Rajesh K Sharma; Ravi K Murthy; K V Chalam
Journal:  Mol Vis       Date:  2010-09-12       Impact factor: 2.367

8.  Persisent ocular hypertension following intravitreal ranibizumab.

Authors:  Sophie J Bakri; Colin A McCannel; Albert O Edwards; Darius M Moshfeghi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-04-19       Impact factor: 3.117

9.  Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury.

Authors:  Kazuaki Nishijima; Yin-Shan Ng; Lichun Zhong; John Bradley; William Schubert; Nobuo Jo; Jo Akita; Steven J Samuelsson; Gregory S Robinson; Anthony P Adamis; David T Shima
Journal:  Am J Pathol       Date:  2007-07       Impact factor: 4.307

10.  Attenuated age-related thinning of peripapillary retinal nerve fiber layer in long eyes.

Authors:  Eun-Ji Kim; Samin Hong; Chan Yun Kim; Eun Suk Lee; Gong Je Seong
Journal:  Korean J Ophthalmol       Date:  2011-07-22
View more
  8 in total

1.  Prophylaxis with intraocular pressure lowering medication and glaucomatous progression in patients receiving intravitreal anti-VEGF therapy.

Authors:  Jeanette Du; James T Patrie; Xiao-Yu Cai; Bruce E Prum; Yevgeniy Shildkrot
Journal:  Int J Ophthalmol       Date:  2022-10-18       Impact factor: 1.645

2.  Effect of Intravitreal Injections on Retinal Imaging Metrics in Glaucomatous and Non-Glaucomatous Eyes.

Authors:  Ronaldo Nuesi; Swarup S Swaminathan
Journal:  Curr Ophthalmol Rep       Date:  2020-06-04

3.  Rates of RNFL Thinning in Patients with Suspected or Confirmed Glaucoma Receiving Unilateral Intravitreal Injections for Exudative AMD.

Authors:  Swarup S Swaminathan; Anne L Kunkler; Ann V Quan; Charles M Medert; Elizabeth A Vanner; William Feuer; Ta Chen Chang
Journal:  Am J Ophthalmol       Date:  2020-12-24       Impact factor: 5.488

4.  Effect of intravitreal ranibizumab and aflibercept injections on retinal nerve fiber layer thickness.

Authors:  Jayoung Ahn; Kyuhwan Jang; Joonhong Sohn; Ji In Park; Daniel Duck-Jin Hwang
Journal:  Sci Rep       Date:  2021-03-03       Impact factor: 4.379

5.  Changes in intraocular pressure in study and fellow eyes in the IVAN trial.

Authors:  Alexander J E Foss; Lauren J Scott; Chris A Rogers; Barney C Reeves; Faruque Ghanchi; Jonathan Gibson; Usha Chakravarthy
Journal:  Br J Ophthalmol       Date:  2016-04-12       Impact factor: 4.638

6.  The effects of intravitreal injections on intraocular pressure and retinal nerve fiber layer: a systematic review and meta-analysis.

Authors:  Victor A de Vries; Fabiana L Bassil; Wishal D Ramdas
Journal:  Sci Rep       Date:  2020-08-06       Impact factor: 4.379

Review 7.  Intraocular Pressure Elevation Following Intravitreal Anti-VEGF Injections: Short- and Long-term Considerations.

Authors:  Ariana M Levin; Craig J Chaya; Malik Y Kahook; Barbara M Wirostko
Journal:  J Glaucoma       Date:  2021-12-01       Impact factor: 2.503

8.  Changes in inner retinal layer thickness in patients with exudative age-related macular degeneration during treatment with anti-vascular endothelial growth factor.

Authors:  Seong Woo Lee; Ha Eun Sim; Jae Yong Park; Jae Suk Kim; In Beom Chang; Young Soon Park; Je Hyung Hwang
Journal:  Medicine (Baltimore)       Date:  2020-04       Impact factor: 1.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.